DMH1: Precision Inhibition of BMP Type I Receptors in Cancer and Organoid Models

Executive Summary: DMH1 (SKU B3686) is a selective small molecule inhibitor targeting bone morphogenetic protein (BMP) type I receptors, specifically ALK2, with an IC₅₀ of 107.9 nM (https://www.apexbt.com/dmh-1.html). This compound exhibits high specificity, does not inhibit VEGF or other kinases such as KDR, ALK5, AMPK, or PDGFRβ (https://doi.org/10.1038/s41467-024-55567-2). DMH1 suppresses Smad1/5/8 phosphorylation and downregulates Id1-3 gene expression, mediating anti-proliferative effects in non-small cell lung cancer (NSCLC) models. In advanced organoid systems, DMH1 facilitates controlled modulation of stem cell self-renewal and differentiation. APExBIO supplies DMH1 as a research-grade powder or 10 mM DMSO solution for reproducible, pathway-specific studies.

Biological Rationale

BMP signaling regulates cell fate, proliferation, and differentiation in diverse tissues. Dysregulation of BMP pathways contributes to oncogenesis, particularly in NSCLC, by promoting uncontrolled cell growth and migration (https://doi.org/10.1038/s41467-024-55567-2). In organoid models, BMP gradients are essential for balancing self-renewal and differentiation, as seen in human intestinal organoid systems. Modulating BMP activity with selective inhibitors such as DMH1 enables researchers to dissect downstream effects on stemness, lineage commitment, and cellular heterogeneity. Unlike pan-kinase inhibitors, DMH1 provides targeted suppression of BMP type I receptors, minimizing off-target effects and enabling precise experimental control.

Mechanism of Action of DMH1

DMH1 is a dorsomorphin analog that binds selectively to the kinase domain of BMP type I receptors, notably ALK2 (ACVR1) and ALK3 (BMPR1A), inhibiting their activity (IC₅₀ for ALK2 = 107.9 nM; ALK3/ALK2 cellular IC₅₀ < 0.5 μM) (https://www.apexbt.com/dmh-1.html). DMH1 does not inhibit VEGF receptor KDR, ALK5, AMPK, or PDGFRβ at relevant concentrations, and shows no interference with p38/MAP kinase or Activin A-induced Smad2 activation. Upon BMP pathway inhibition, phosphorylation of Smad1/5/8 is reduced, leading to downregulation of Id1, Id2, and Id3 gene expression. This cascade impedes NSCLC cell migration, invasion, proliferation, and induces apoptosis. In organoid cultures, DMH1 enables reversible, tunable control over the balance of stem cell self-renewal and differentiation (https://doi.org/10.1038/s41467-024-55567-2).

Evidence & Benchmarks

• DMH1 inhibits ALK2 kinase activity with an IC₅₀ of 107.9 nM, demonstrating high potency and specificity (https://www.apexbt.com/dmh-1.html).
• DMH1 does not inhibit KDR (VEGF receptor), ALK5, AMPK, or PDGFRβ at concentrations effective for BMP inhibition (https://doi.org/10.1038/s41467-024-55567-2).
• In NSCLC A549 xenograft mouse models, DMH1 treatment reduces tumor volume by approximately 50% and extends tumor doubling time (https://www.apexbt.com/dmh-1.html).
• DMH1 blocks Smad1/5/8 phosphorylation and downregulates Id1, Id2, and Id3 expression, correlating with reduced proliferation and increased apoptosis in NSCLC cell lines (https://doi.org/10.1038/s41467-024-55567-2).
• In human intestinal organoids, DMH1 enables controlled shifts between stem cell self-renewal and differentiation, increasing cellular diversity under a single culture condition (https://doi.org/10.1038/s41467-024-55567-2).

For a deeper exploration of DMH1 in cell viability and organoid workflows, see this scenario-driven assessment—whereas the present article provides updated benchmarks and translational context for cancer and organoid research.

Applications, Limits & Misconceptions

DMH1 is used in:

• Preclinical NSCLC studies to assess BMP pathway roles in tumorigenesis and therapy response.
• Human and mouse organoid models to modulate self-renewal versus differentiation, especially in intestinal, hepatic, and pancreatic systems.
• Dissecting BMP-driven signaling in developmental and disease contexts, with minimal off-target kinase inhibition.
• High-throughput screening for pathway modulators in organoid-based drug discovery workflows.

Common Pitfalls or Misconceptions

• DMH1 is not a pan-kinase inhibitor: It lacks activity against KDR, ALK5, AMPK, and PDGFRβ at working concentrations.
• Limited solubility in water or ethanol: DMH1 must be dissolved in DMSO (≥9.51 mg/mL), and solutions should be freshly prepared or stored short-term at -20°C.
• Does not inhibit Activin A/Smad2 signaling: Researchers studying TGF-β/Activin pathways should not expect DMH1 to affect Smad2 phosphorylation.
• Not suitable for in vivo oral or aqueous dosing: Due to poor aqueous solubility, in vivo use requires appropriate vehicle formulation.
• Specificity must be confirmed in new cell contexts: Differential expression of BMP receptors may influence DMH1 efficacy.

For further guidance on DMH1's use in high-fidelity organoid engineering, see this methodology-focused review; this current article clarifies selectivity benchmarks and application boundaries.

Workflow Integration & Parameters

DMH1 is supplied by APExBIO as a solid powder or 10 mM solution in DMSO. It is insoluble in water and ethanol, but soluble in DMSO at concentrations ≥9.51 mg/mL. For optimal solubility, warm to 37°C and utilize ultrasonic shaking if necessary. Solutions are stable for short-term use only and should be stored at -20°C. Typical working concentrations in cell-based assays range from 0.1–10 μM, with pathway inhibition observed at sub-micromolar doses. Prior to workflow integration, titrate DMH1 to determine minimal effective concentrations in the intended biological system. In vivo studies require careful formulation due to solubility constraints. DMH1 enables rapid, reversible pathway modulation in both cancer cell lines and organoid cultures, with minimal off-target effects.

For practical workflow integration in advanced organoid systems, see this application-oriented article, which DMH1's unique selectivity profile further extends by supporting dynamic, tunable cell fate control.

Conclusion & Outlook

DMH1 (SKU B3686) is a validated, highly selective BMP type I receptor inhibitor with proven efficacy in NSCLC and organoid research. Its nanomolar potency for ALK2/ALK3, absence of significant off-target kinase inhibition, and robust performance in preclinical models position it as a gold-standard tool for precise pathway modulation. APExBIO provides DMH1 in validated formats optimized for research reproducibility. Ongoing advances in organoid technology and cancer biology will continue to leverage DMH1 for dissecting BMP-driven processes, with future work aimed at expanding its application in high-throughput screening and translational studies.